广发策略：从不买就跑输到买了就跑输——再看南下定价权

Group 1 - Since September 2024, the proportion of southbound capital transactions has rapidly increased to 20%-30%, nearly doubling compared to before 2024 [2][5] - In 2025, both active and passive foreign capital have become synchronous indicators of the Hong Kong stock market, showing no leading characteristics [2][5] - During sharp declines or corrections in the Hong Kong stock market, southbound capital tends to buy against the trend [2][5] Group 2 - Each round of pricing power competition typically begins with the optimization of the Stock Connect policy or the influx of incremental capital, which usually flows into dividend and scarce assets [5] - Net outflows of southbound capital often occur in response to adverse industry policies or external macroeconomic environments, particularly in sectors where foreign capital pricing power is increasing, such as software services, hardware equipment, consumer services, and discretionary retail [5][12] - Industries less likely to experience significant net outflows include those favored by long-term capital, such as banking, telecommunications, and public utilities, unless there are clear adverse policies affecting the sector [5][12] Group 3 - The proportion of medium to long-term capital in the current round of southbound capital inflow into Hong Kong stocks has increased, with insurance capital making 41 stakes, 35 of which are in H-shares, marking the highest record in the past decade [8] - Key industries for increased holdings include discretionary retail, finance (banking, insurance), innovative pharmaceuticals, software services, and hardware equipment [8] Group 4 - Current industries with pricing power for southbound capital and Chinese capital include semiconductors and dividend stocks, while industries lacking pricing power include internet, hardware equipment, software services, home appliances, and media [11][12] - Active management public funds have low pricing power in the Hong Kong stock market, focusing heavily on AI-related CSP giants, electronics, and innovative pharmaceuticals [16]